Evidence map›Paper›PMID 35579223›Full record

ReviewThe European journal of general practice2022

Chronic hepatitis C: Diagnosis and treatment made easy.

Naim Abu-Freha, Binil Mathew Jacob, Ali Elhoashla, Zaid Afawi, Talab Abu-Hammad, Foad Elsana, Sergey Paz, Ohad Etzion

Open access · goldAbstract readReview
In one paragraph

Review in The European journal of general practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Risk factors for HCV infection in Georgia: A case-control study.Journal of infection in developing countries · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. [Seroprevalence and risk factor for hepatitis C in Nogales, Sonora].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Naim Abu-FrehaThe Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.ORCID 0000-0002-4844-3308
Binil Mathew JacobMedical School for International Health, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Ali ElhoashlaClalit Health Services, Beer-Sheva, Israel.
Zaid AfawiClalit Health Services, Beer-Sheva, Israel.
Talab Abu-HammadClalit Health Services, Beer-Sheva, Israel.
Foad ElsanaClalit Health Services, Beer-Sheva, Israel.
Sergey PazClalit Health Services, Beer-Sheva, Israel.
Ohad EtzionThe Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Clalit Health Services · ILBen-Gurion University of the Negev · ILErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C Virus (HCV) is a common cause of chronic liver disease and its ensuing complications. In the last years, there has been a revolution of the treatment for patients with HCV regarding efficacy, simplicity, safety and duration of treatment. The role of the family physician is vital in all steps of care: screening, diagnosis, linkage to treatment, treatment and follow-up.

objectivesThis review aims to summarise the family physician and the important updated recommendations for diagnosis and treatment of patients with chronic HCV.

methodsThe updated recommendations were reviewed and summarised in a short and simple review.

resultsPatients with any risk factor for HCV should first be screened for HCV antibodies. In the case of positive antibodies, reflex testing for RNA polymerase chain reaction (PCR) should be done without waiting for genotype. For patients with positive PCR, fibrosis assessment should be conducted using laboratory panels (Fibrosis-4 index (FIB-4) or aspartate aminotransferase to platelet ratio index (APRI)); if advanced fibrosis is suspected, additional non-invasive fibrosis assessment is needed, such as fibrotest or liver elastography. Naïve non-cirrhotic or compensated cirrhosis (Child-Pugh-Score A) could be treated with pangenotypic drugs, Glecaprevir/pibrentasvir (Maviret) for eight weeks, or Sofosbuvir/velpatasvir (Epclusa) for 12 weeks.

conclusionPatients without advanced fibrosis and comorbidities can be treated by the educated family physician. However, patients with comorbidities, cirrhosis or coinfection (HIV, Hepatitis B Virus (HBV)) should be referred to the liver clinic. In case of screening patients with risk factors or likelihood of dormant HCV, health organisations should provide the appropriate resources, logistics, finances and workforce.

Indexed as

Hepatitis CHepatitis C, ChronicAminoisobutyric AcidsAntiviral AgentsCyclopropanesHepacivirusHumansLactams, MacrocyclicLeucineLiver CirrhosisAminoisobutyric AcidsAntiviral AgentsCyclopropanesLactams, MacrocyclicLeucinedirect antiviral agentsfamily physiciansHepatitis C virus

Identifiers

PMID35579223
PMCPMC9116263
OpenAlexW4280608070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.